PMBS 1000%? - 500 Beiträge pro Seite
eröffnet am 25.01.14 09:56:11 von
neuester Beitrag 11.10.14 13:10:26 von
neuester Beitrag 11.10.14 13:10:26 von
Beiträge: 19
ID: 1.190.737
ID: 1.190.737
Aufrufe heute: 0
Gesamt: 6.693
Gesamt: 6.693
Aktive User: 0
ISIN: US7460942003 · WKN: A12DA0
0,0001
USD
+9.900,00 %
+0,0001 USD
Letzter Kurs 02.04.19 Nasdaq OTC
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 41,00 | +41,38 | |
| 1,9500 | +26,62 | |
| 0,6400 | +16,36 | |
| 3,9700 | +12,15 | |
| 1.260,00 | +9,37 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 165,70 | -9,70 | |
| 4,0000 | -11,11 | |
| 9,8500 | -15,81 | |
| 1,6800 | -22,58 | |
| 0,6300 | -30,00 |
Feedback
PuraMed Bioscience was founded in 2006 and is based in Schofield, Wisconsin. The company began trading under the symbol PMBS in May 2008.
PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.
For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.
PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.
A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.
In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.
The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.
The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.
Market Drivers
50 million migraine sufferers
70 million insomnia sufferers
Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.
Unique PuraMed Delivery System
Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution
Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS
Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.
News and Developments
PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.
Market Opportunity
LipiGesic® M – Migraine
Over 50 million suffer
1 billion + occurrences/yr.
Majority rely on non prescription medications
Current migraine relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® H – Tension
Over 102 million suffer from chronic and episodic tension-type headache
1 billion occurrences/year
Current tension relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® PM -Insomnia
70 million suffer
5 billion occurrences/yr.
Current insomnia products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. The company emphasizes science as a key component for its success. By partnering with world-class researchers and physicians to conduct and publish world-class research on its products, PuraMed believes it will gain acceptance and credibility from consumers and medical professionals at a much faster and greater rate.
For its initial product line, the company uses a unique sublingual (under the tongue) delivery system, taking advantage of the capillary structure under the tongue which is very close to the surface. Sublingual delivery enables fast absorption and action. It also bypasses the liver and digestive system, avoiding the destruction of the active ingredients by these organs. This allows for lower dosage requirements and increased safety.
PuraMed is currently launching its first product, LipiGesic® M for the treatment of migraine headaches, into the U.S. national retail market. This is a very large market, with approximately 50 million sufferers in the U.S. alone. Migraine headaches are considered to be the most expensive brain disorder in the U.S., costing the economy more than $31 billion in 2010.
A multi-site, double-blind placebo-controlled study, conducted by three nationally recognized headache specialists, was published in a top-tier medical journal in July 2011. This study concluded that LipiGesic M is a highly effective and safe first-line abortive treatment for migraine sufferers. When compared to a meta-analysis of the number one selling prescription treatment, the results of the LipiGesic® M study show it offers a number of advantages. In addition to superior pain relief, LipiGesic® M provides relief from the associated symptoms. It also offers a vastly improved safety profile, no known drug interactions, does not require a physician visit or prescription, and it cuts the treatment cost by at least 75%. These are very powerful advantages, especially for a non-prescription treatment.
In addition to LipiGesic® M, the company also intends to launch two other sublingual gel products in its LipiGesic product line. LipiGesic® H is designed to provide rapid relief from tension-type headaches. More than 100 million people suffer from chronic and episodic tension-type headaches in the U.S. LipiGesic PM is designed to provide relief from insomnia and other sleep disorders. There are more 70 million people who suffer from sleep disorders in the U.S. alone.
The LipiGesic product line effectively addresses three large underserved markets. In addition, the company has approximately 20 other unique products in its pipeline, addressing a broad spectrum of self-limiting disease states including acne, rosacea, age spots and canker sores.
The company believes that by improving the efficiency of delivery, it can provide products that offer superior relief versus current treatment while also dramatically increasing safety and cutting treatment costs significantly.
Market Drivers
50 million migraine sufferers
70 million insomnia sufferers
Total economic cost of migraine headaches exceeded $31 Billion in the United States in 2010. Migraine headaches represent the most costly brain disorder in the United States.
By using sublingual (under the tongue) delivery, the medication is able to work much faster than taking pills.
Sublingual delivery also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This enables the Company to achieve broad distribution quickly and at low cost.
There are NO serious adverse events associated with LipiGesic® products for migraine, insomnia or tension headaches.
Unique PuraMed Delivery System
Sublingual delivery (meaning under the tongue) is a superior delivery system to pills because the sublingual delivery works much faster and lower dosage is required. The capillaries under the tongue are extremely close to the surface creating very fast absorption and action. Sublingual delivery not only works faster than most other delivery systems but it also avoids the "first pass" effect, common with the use of pills, whereby the strength of a drug is greatly reduced before it reaches the systemic circulation. Avoiding this "first pass effect" allows for lower dosages.
Distribution
Non-prescription products reach U.S. consumers through approximately 80,000 chain and independent drug, food and mass merchandise retailers (including club stores), 116,000 convenience stores, 4,500 specialty nutrition and health stores, as well as via direct marketing through television, radio, catalogues and the Internet. PuraMed plans to market and distribute its products through mainstream chain drug, independent drug, mass merchandiser, food and warehouse stores. Company founders have experience that includes placing products in 50,000 stores nationwide through its brokers and representatives. This background will enable the Company to achieve broad distribution quickly and at better rates.
RECENT HIGHLIGHTS
Distributing product in Walgreens stores across the nation, with additional key retail chains to follow.
News and Developments
PuraMed BioScience announced today that the independent clinical study of their LipiGesic® M migraine product has been accepted for publication by a top ranked medical journal. The clinical study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic® M for the treatment of acute migraines.
PuraMed BioScience announced today that it has entered into an agreement with Double Pump, Inc. designed to enhance marketing efforts and product awareness surrounding the national retail launch of the Company"s products.
Market Opportunity
LipiGesic® M – Migraine
Over 50 million suffer
1 billion + occurrences/yr.
Majority rely on non prescription medications
Current migraine relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® H – Tension
Over 102 million suffer from chronic and episodic tension-type headache
1 billion occurrences/year
Current tension relief products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
LipiGesic® PM -Insomnia
70 million suffer
5 billion occurrences/yr.
Current insomnia products are marginally effective and have significant side effects
No "alternative" competition
Bests "standard" products
Recurring, non-seasonal
Unique delivery platform
das Migränemittel LipiGesic M wird seit anfang 2014 verkauft.weiterhin planen die ein desinfektionsmittel in china an den mann zubringen.
bei einer MK von 200k sollten hier paar prozente drinn sein.
bei einer MK von 200k sollten hier paar prozente drinn sein.
Antwort auf Beitrag Nr.: 46.303.921 von ultrawuffsn am 25.01.14 10:01:30Kurs ist letzte Woche angesprungen und kam jetzt die letzen tage wieder zurück.ich bin mit 1. posi drinn.Der chart sieht gut aus wenn man das bei otc sagen kann.
mein 1. persönliches ziel ist 0,010.
mein 1. persönliches ziel ist 0,010.
Antwort auf Beitrag Nr.: 46.303.937 von ultrawuffsn am 25.01.14 10:05:41Expansion to Additional Retail Drug Chains
Currently, LipiGesic M is distributed in approximately 15,000 Walgreen’s and CVS/pharmacy stores across the United States. PuraMed plans to expand the retail placement of LipiGesic M, its clinically tested, natural migraine relief product into an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
Currently, LipiGesic M is distributed in approximately 15,000 Walgreen’s and CVS/pharmacy stores across the United States. PuraMed plans to expand the retail placement of LipiGesic M, its clinically tested, natural migraine relief product into an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
Antwort auf Beitrag Nr.: 46.303.951 von ultrawuffsn am 25.01.14 10:12:02mal sehn wann die ersten verkaufszahlen präsentiert werden.
Trading Spotlight
Antwort auf Beitrag Nr.: 46.304.007 von ultrawuffsn am 25.01.14 10:24:38Russ Mitchell, der Vorsitzende und CEO von PuraMed BioScience, kommentierte kürzlich in einem Interview, dass mit fast 60 Millionen Amerikaner leiden unter Migräne das Umsatzpotenzial für LipiGesic ™ M, die over-the-counter Migräne Erleichterung Produkt konnte über 50 Millionen US-Dollar jährlich generieren.
Interview-Highlights
- Umsatzpotenzial LipiGesic M Könnte Exceed $ 50 Millionen
- Ausbau Ketten Shop Retail Distribution
- Mögliche Patent Portfolio Acquisition Millionen wert
- Marktkapitalisierung derzeit unter $ 1 Million
Mr. Mitchell diskutierten auch den Vertriebsausbau für ihre over-the-counter (OTC) Migräne Schmerzmittel Produkt, das derzeit in Geschäften wie Walgreen und CVS / pharmacy ist, und plant, den Einzelhandel Platzierung auf weitere 21.000 Verkaufsstellen gezielt zu erweitern, einschließlich Großabnehmern wie Wal-Mart und Target, Lebensmittel-Handelsketten wie SuperValu, Kroger, Safeway und, wie auch regionale Drogerieketten.
übersetzt mit google,ein interwiev von 2013.
jetzt wird das mittel rezeptfrei verkauft.
Interview-Highlights
- Umsatzpotenzial LipiGesic M Könnte Exceed $ 50 Millionen
- Ausbau Ketten Shop Retail Distribution
- Mögliche Patent Portfolio Acquisition Millionen wert
- Marktkapitalisierung derzeit unter $ 1 Million
Mr. Mitchell diskutierten auch den Vertriebsausbau für ihre over-the-counter (OTC) Migräne Schmerzmittel Produkt, das derzeit in Geschäften wie Walgreen und CVS / pharmacy ist, und plant, den Einzelhandel Platzierung auf weitere 21.000 Verkaufsstellen gezielt zu erweitern, einschließlich Großabnehmern wie Wal-Mart und Target, Lebensmittel-Handelsketten wie SuperValu, Kroger, Safeway und, wie auch regionale Drogerieketten.
übersetzt mit google,ein interwiev von 2013.
jetzt wird das mittel rezeptfrei verkauft.
Wohl ein paar Jahre zu spät dran!Gerade in den USA ist seit ein paar Jahren wieder ein jahrtausende Jahre altes Naturheilmittel auf dem Vormarsch, mittlerweile in 21 Bundesstaaten auf Rezept, in einigen sogar bereits rezeptfrei!
Da dieses Naturheilmittel bekanntlich rd. 1/3 aller herkömmlichen Arzneimittel ersetzen kann und eben nicht nur bei schweren Krankheiten, wie Multipler Sklerose, grauem Star, begleitend zur Chemo-Behandlung von Krebspatienten, Tourette, Übelkeit, Depressionen usw. usf... eingesetzt werden kann, sondern auch DAS Migränemittel schlechthin ist, wüßte ich beim "besten" Willen keinen Grund mehr, warum man sich einen Chemiecocktail einpfeifen sollte, obwohl man auch genauso gut einen leckeren Bio-Keks, ohne potenziell schädlichen Nebenwirkungen, essen könnte!
Mal lesen:
http://www.cannabismedizin.at/wp-content/uploads/MedizinZuku…
Glaube Du bist bei Cannabis zu spät dran, denn diese Megablase platz sehr bald.
Cannabis verursacht mehr Kopfschmerzen als dass es hilft, zieht weitere Nebenwirkungen nach sich und wird immer noch von vielen als Suchtmittel verschrien. Nicht ohne Grund wurde Cannabis als Arznei die ganze Zeit verboten.
Da spielen in den USA gerade ein paar große Institutionen mit, um an der sich aufblähenden Blase zu verdienen.
Mit dem Migränemittel von Puramed hat das alles aber nichts zu tun.
LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
SCHOFIELD, Wis., Nov. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.
In the article entitled, "Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question," the authors warn physicians not to "recommend prolonged or frequent use of over-the-counter (OTC) pain medications for headache." The American Headache Society (AHS) article recommended that OTC headache pain relievers should not be used more than twice a week to avoid the incidence of "medication overuse headache," especially when the medications contain caffeine. The article goes on to cite the dangers of liver damage caused by the overuse of acetaminophen and gastrointestinal bleeding caused by overuse of nonsteroidal anti-inflammatory drugs.
"Having a product like LipiGesic M that does not produce 'medication overuse headache' is important in light of the latest report published by the AHS," said Russell Mitchell, CEO of PuraMed BioScience. "There have been no reported occurrences of LipiGesic M causing a rebound headache no matter how frequently a person uses it. LipiGesic M's patented formulation of feverfew and ginger also has not been shown to cause liver damage, stomach bleeding, or other adverse side effects."
When writing the "Choosing Wisely in Headache Medicine: ..." article published in the November/December 2013 issue of Headache, the authors asked AHS members to suggest tests, procedures, or treatments in headache medicine that were commonly overused or misused. The five suggestions selected "were associated with poor patient outcomes, low value care or documented overuse or misuse," the study said.
"LipiGesic M is not like the pain relievers that are cited in the study," said Mitchell. "Based on the results of our clinical trial, LipiGesic M performs more like a prescription migraine medication than an OTC migraine formulation, but without the unwanted side effects associated with either product category."
This fact was also stated in Advances in Drug Development for Acute Migraine, an article published in Drugs medical journal in December 2012. Speaking of LipiGesic M, the authors, including headache expert Dr. Roger Cady, said, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."
The Cleveland Clinic website also lists many medications that can cause rebound headache. The list includes: "aspirin, sinus relief medications, acetaminophen, nonsteroidal anti-inflammatory medications (NSAIDs), sedatives for sleep, codeine and prescription narcotics, and over-the-counter combination headache remedies containing caffeine (such as Anacin®, Excedrin®, Bayer Select®, and others)." http://my.clevelandclinic.org/disorders/Headaches/hic_Reboun…
"Recently there have been an increased number of Food and Drug Administration safety warnings associated with acetaminophen and other OTC pain medications," said Mitchell. "People forget that many OTC medications were only available as prescriptions when they were first introduced. That's why it is personally gratifying to offer a highly effective treatment for acute migraine that does not cause the harmful side effects mentioned by the report."
Currently, PuraMed BioScience has 68,702,155 shares outstanding.
Cannabis verursacht mehr Kopfschmerzen als dass es hilft, zieht weitere Nebenwirkungen nach sich und wird immer noch von vielen als Suchtmittel verschrien. Nicht ohne Grund wurde Cannabis als Arznei die ganze Zeit verboten.
Da spielen in den USA gerade ein paar große Institutionen mit, um an der sich aufblähenden Blase zu verdienen.
Mit dem Migränemittel von Puramed hat das alles aber nichts zu tun.
LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
SCHOFIELD, Wis., Nov. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.
In the article entitled, "Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question," the authors warn physicians not to "recommend prolonged or frequent use of over-the-counter (OTC) pain medications for headache." The American Headache Society (AHS) article recommended that OTC headache pain relievers should not be used more than twice a week to avoid the incidence of "medication overuse headache," especially when the medications contain caffeine. The article goes on to cite the dangers of liver damage caused by the overuse of acetaminophen and gastrointestinal bleeding caused by overuse of nonsteroidal anti-inflammatory drugs.
"Having a product like LipiGesic M that does not produce 'medication overuse headache' is important in light of the latest report published by the AHS," said Russell Mitchell, CEO of PuraMed BioScience. "There have been no reported occurrences of LipiGesic M causing a rebound headache no matter how frequently a person uses it. LipiGesic M's patented formulation of feverfew and ginger also has not been shown to cause liver damage, stomach bleeding, or other adverse side effects."
When writing the "Choosing Wisely in Headache Medicine: ..." article published in the November/December 2013 issue of Headache, the authors asked AHS members to suggest tests, procedures, or treatments in headache medicine that were commonly overused or misused. The five suggestions selected "were associated with poor patient outcomes, low value care or documented overuse or misuse," the study said.
"LipiGesic M is not like the pain relievers that are cited in the study," said Mitchell. "Based on the results of our clinical trial, LipiGesic M performs more like a prescription migraine medication than an OTC migraine formulation, but without the unwanted side effects associated with either product category."
This fact was also stated in Advances in Drug Development for Acute Migraine, an article published in Drugs medical journal in December 2012. Speaking of LipiGesic M, the authors, including headache expert Dr. Roger Cady, said, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."
The Cleveland Clinic website also lists many medications that can cause rebound headache. The list includes: "aspirin, sinus relief medications, acetaminophen, nonsteroidal anti-inflammatory medications (NSAIDs), sedatives for sleep, codeine and prescription narcotics, and over-the-counter combination headache remedies containing caffeine (such as Anacin®, Excedrin®, Bayer Select®, and others)." http://my.clevelandclinic.org/disorders/Headaches/hic_Reboun…
"Recently there have been an increased number of Food and Drug Administration safety warnings associated with acetaminophen and other OTC pain medications," said Mitchell. "People forget that many OTC medications were only available as prescriptions when they were first introduced. That's why it is personally gratifying to offer a highly effective treatment for acute migraine that does not cause the harmful side effects mentioned by the report."
Currently, PuraMed BioScience has 68,702,155 shares outstanding.
Alles Lobbyisten, die Cannabis pushen.
Antwort auf Beitrag Nr.: 46.304.029 von ultrawuffsn am 25.01.14 10:29:35auf i-hub sehr starkes interresse.da bin ich heute mal gespannt.
Antwort auf Beitrag Nr.: 46.311.287 von ultrawuffsn am 27.01.14 06:24:17
auf i-hub hat mal einer ne rechnung aufgemacht.
CVS = more than 7,600 CVS/pharmacy stores + Onlineshop
If they sold 1 pack /week in every store = 30400 Packs / Month!
Let them get 50% of the Storeprice (10$) = 304.000 $ / Month!
Thats only from CVS-Stores and only 1 pack / week !!!
Now take a look at the Market Value1 $311,722 a/o Jan 24, 2014 !!
I think its undervalued extremly! wink
auf i-hub hat mal einer ne rechnung aufgemacht.
CVS = more than 7,600 CVS/pharmacy stores + Onlineshop
If they sold 1 pack /week in every store = 30400 Packs / Month!
Let them get 50% of the Storeprice (10$) = 304.000 $ / Month!
Thats only from CVS-Stores and only 1 pack / week !!!
Now take a look at the Market Value1 $311,722 a/o Jan 24, 2014 !!
I think its undervalued extremly! wink
Antwort auf Beitrag Nr.: 46.311.343 von ultrawuffsn am 27.01.14 07:28:37läuft langsam an die bude.wird demnächst promotet.
schlußkurs 0,028
morgen dann angriff auf das letzte hoch bei 0,040.
schlußkurs 0,028
morgen dann angriff auf das letzte hoch bei 0,040.
der Angriff läuft...
heute bei 44
beim dritten Mal gelingt der Ausbruch
Canabismedizin hört sich interessant an ....
heute bei 44
beim dritten Mal gelingt der Ausbruch
Canabismedizin hört sich interessant an ....
48 / 49
das riecht doch nach Ausbruch
das riecht doch nach Ausbruch
rt 57
Wir steigen heute um 58 % ohne news
und schließen auf TH
Da kommt doch was ......
und schließen auf TH
Da kommt doch was ......
Hi, will hier meinen Restbestand entsorgen, um wenigstens Verlustvorträge zu generieren.
Meine Bank teilt mir mit, dass ein handel nicht mgl. ist.
Weiss jemand mehr? Wird die Aktie noch gehandelt?
Meine Bank teilt mir mit, dass ein handel nicht mgl. ist.
Weiss jemand mehr? Wird die Aktie noch gehandelt?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,56 | |
| 0,00 | |
| -0,59 | |
| -0,35 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 93 | ||
| 66 | ||
| 50 | ||
| 46 | ||
| 42 | ||
| 42 | ||
| 37 | ||
| 35 | ||
| 27 |
